Efficacy of Probiotic Lactobacillus Crispatus M247 in Promoting High-risk Human Papillomavirus (HR-HPV) Infection Clearance and Modifying Vaginal Microbiota
Key facts
- Who runs it
- Liaquat University of Medical & Health Sciences
- Where
- Italy3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 66 people enrolled
- Started
- 5 Jan 2022
- Ended
- 30 Dec 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Lactobacillus crispatus M247 (Crispact®)
- Placebo
- Record updated
- 4 June 2025
Who can take part
- Age
- 18 years to 69 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Women aged 18-69 years
- First diagnosis of HR-HPV infection via DNA-HPV screening
- Cytology results showing ASC-US or LSIL
- Negative colposcopy or biopsy (absence of lesions)
- Ability to provide written informed consent
Who cannot take part
- Prior HPV vaccination
- Current treatment with antibiotics, immunomodulatory, or immunosuppressive therapies
- History of cervical treatments for pre-neoplastic pathology
- Diagnosed immune system or neoplastic diseases requiring chemotherapy
- Known hypersensitivity to product components
- Cytology showing HSIL (High-Grade Squamous Intraepithelial Lesion) requiring treatment
- Pregnancy, lactation, or planning to become pregnant within 6 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This clinical trial evaluates the efficacy of the probiotic strain Lactobacillus crispatus M247 in promoting the clearance of genital high-risk human papillomavirus (HR-HPV) infection and restoring the balance of the vaginal microbiota. The study adopts a multicenter, randomized, single-blind, longitudinal, prospective design involving HR-HPV-positive patients. Primary outcomes include HR-HPV clearance rates and microbiota composition changes.
The 2 groups in the trial
- Probiotic supplement Lactobacillus crispatus M247 groupTreatment being tested
Participants in this group will receive probiotic supplement Lactobacillus crispatus M247 (Crispact®) in stick form, administered orally at a dose of one stick per day for 4 months. Each stick contains 20 billion CFU of L. crispatus M247.
Treatment: Lactobacillus crispatus M247 (Crispact®)
- Control GroupPlacebo, for comparison
Participants in the control group will receive a placebo identical in appearance and packaging to the experimental product, administered orally at a dose of one stick per day for 4 months.
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Evaluation of the Efficacy of Lactobacillus Crispatus M247 Administration in Promoting Clearance of Genital HR-HPV Infection and Modulating the Vaginal Microbiota: A Multicenter, Randomized, Placebo-Controlled, Single-Blind, Longitudinal, Prospective Clinical Trial
- Record updated
- 4 June 2025